Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Structural characterization of the interactions between A3F and HIV-1 viral proteins
EF 2013-14
Résumé
AIDS is a global pandemic. Those with AIDS experience immune system failure and increased risk of life threatening opportunistic infections. AIDS is caused by infection with the sexually transmitted virus HIV, which is a retrovirus that permanently incorporates its genetic information into the host genome resulting in chronic life-long infection. As of 2008, the Public Health Agency of Canada estimates there are over 65,000 cases of HIV in Canada, with 2,300-4,300 new cases in 2008 alone and over 33.3 million people worldwide living with HIV. Thus, the Government of Canada and the Canadian Institute for Health Research has made HIV/AIDS research a priority area.
Currently, highly active anti-retroviral therapy (HAART) is employed to treat HIV infection. While HAART is effective, it is imperfect and often has severe side effects including digestive problems, diarrhea, increased risk of diabetes, and a risk of liver failure. More importantly, given the swift evolution of the virus, resistance to current drug therapies is becoming a major problem. All Health Canada drugs for HIV/AIDS target viral proteins, and are thus prone to viral escape. This necessitates an urgent need for the development of radically different therapeutics than those currently used. One strategy would be to harness the power of our immune system. During HIV infection, our body has developed multiple lines of defenses, such as APOBEC3, against the virus. In turn, HIV has developed intricate countermeasures, such as the viral protein HIV-1 Vif, to survive. Currently, the tug-of-war between host and virus is poorly understood from an atomic-level perspective. High-resolution atomic structures of APOBEC3 are needed to understand their function and to provide a blueprint into the development of novel HIV/AIDS treatments against a cellular target. However, few structures of these innate immune factors and HIV proteins have been solved due to challenges in producing these proteins in sufficient quantities and stability for structural work. In order to address these issues, we will employ a novel and efficient expression and crystallization platform that was instrumental in the determination of other viral structures.
By improving our understanding of these host restriction factors and their regulation we will advance our understanding of the immune system from both a basic science perspective and from a drug development perspective. Drugs targeting APOBEC3 proteins or drugs based on how they inhibit viral proteins could both prove to be new classes of anti-viral drugs. This work aims to further translate recent basic science advances in APOBEC3 by achieving a comprehensive structural understanding of the HIV-host interactions that could ultimately lead to the design of new classes of anti-retroviral drugs that target human immune system components, instead of rapidly evolving viral components, to benefit HIV-infected patients in Canada and the world.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
312040
Name
Taylor Matthew W
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Structural characterization of the interactions between A3F and HIV-1 viral proteins
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Bli; Immunology; Innate Immunity; Protein Interaction; Qpcr; Saxs; Signaling; Structural Biology; Virology; X-Ray Crystallography
Abstract
AIDS is a global pandemic. Those with AIDS experience immune system failure and increased risk of life threatening opportunistic infections. AIDS is caused by infection with the sexually transmitted virus HIV, which is a retrovirus that permanently incorporates its genetic information into the host genome resulting in chronic life-long infection. As of 2008, the Public Health Agency of Canada estimates there are over 65,000 cases of HIV in Canada, with 2,300-4,300 new cases in 2008 alone and over 33.3 million people worldwide living with HIV. Thus, the Government of Canada and the Canadian Institute for Health Research has made HIV/AIDS research a priority area.
Currently, highly active anti-retroviral therapy (HAART) is employed to treat HIV infection. While HAART is effective, it is imperfect and often has severe side effects including digestive problems, diarrhea, increased risk of diabetes, and a risk of liver failure. More importantly, given the swift evolution of the virus, resistance to current drug therapies is becoming a major problem. All Health Canada drugs for HIV/AIDS target viral proteins, and are thus prone to viral escape. This necessitates an urgent need for the development of radically different therapeutics than those currently used. One strategy would be to harness the power of our immune system. During HIV infection, our body has developed multiple lines of defenses, such as APOBEC3, against the virus. In turn, HIV has developed intricate countermeasures, such as the viral protein HIV-1 Vif, to survive. Currently, the tug-of-war between host and virus is poorly understood from an atomic-level perspective. High-resolution atomic structures of APOBEC3 are needed to understand their function and to provide a blueprint into the development of novel HIV/AIDS treatments against a cellular target. However, few structures of these innate immune factors and HIV proteins have been solved due to challenges in producing these proteins in sufficient quantities and stability for structural work. In order to address these issues, we will employ a novel and efficient expression and crystallization platform that was instrumental in the determination of other viral structures.
By improving our understanding of these host restriction factors and their regulation we will advance our understanding of the immune system from both a basic science perspective and from a drug development perspective. Drugs targeting APOBEC3 proteins or drugs based on how they inhibit viral proteins could both prove to be new classes of anti-viral drugs. This work aims to further translate recent basic science advances in APOBEC3 by achieving a comprehensive structural understanding of the HIV-host interactions that could ultimately lead to the design of new classes of anti-retroviral drugs that target human immune system components, instead of rapidly evolving viral components, to benefit HIV-infected patients in Canada and the world.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Taylor, Matthew W
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~